Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN2A | Q99250 | 3/20 | 0.62 |
| ▸ | HPGDS | O60760 | 2/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.51 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | BRS3 | P32247 | 1/20 | 0.44 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758675 | 0.93 | SCN2A (0.54) | SCN2AHPGDSPDE10ANPY5RTRPV1 | |
| SCHEMBL5756074 | 0.88 | SCN2A (0.49) | SCN2AHPGDSPDE10ANPY5RTRPV1 | |
| SCHEMBL5758399 | 0.85 | SCN2A (0.47) | SCN2AHPGDSNPY5RTRPV1S1PR1 | |
| SCHEMBL5758643 | 0.83 | HPGDS (0.62) | SCN2AHPGDSPDE10ANPY5RBRS3 | |
| SCHEMBL13960334 | 0.82 | HPGDS (0.61) | SCN2AHPGDSPDE10ANPY5RS1PR1 | |
| SCHEMBL5756347 | 0.81 | NPY5R (0.47) | SCN2AHPGDSNPY5RTRPV1SSTR3 | |
| SCHEMBL25303515 | 0.77 | SCN2A (0.55) | SCN2APDE10ANPY5RTRPV1SSTR3 | |
| SCHEMBL25833757 | 0.77 | SCN2A (0.55) | SCN2APDE10ANPY5RTRPV1SSTR3 | |
| SCHEMBL8196736 | 0.77 | KIF11 (0.43) | SCN2AKIF11TRPV1 | |
| SCHEMBL5759555 | 0.76 | HPGDS (0.53) | SCN2AHPGDSPDE10ANPY5RBRS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | claimed |
| US-20030149089-A1 | Antibacterial compounds | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | claimed |
| EP-1194144-B1 | ANTIBACTERIAL COMPOUNDS | AFFINIUM PHARM INC (CA) | 2006-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149089-A1 | Antibacterial compounds | MRPL21, MRPS28, SPOUT1 | SCN2A 1133/4885HPGDS 2610/4885PDE10A 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.